Artemis Medicare Services Ltd
Artemis Medicare Services Ltd (AMSL) was incorporated on 2004, by the promoters of the Apollo Tyres Group, is engaged in healthcare business. AMSL operates a 318-bedded multi-specialty tertiary care hospital in Gurgaon. It has specialization in various segments like Orthopedics & Joint Replacement, Oncology, Cardiovascular, Neurosciences and Bariatric & Minimally Invasive Surgery. AMSL has been awarded with the NABH accreditation.
- Market Cap ₹ 2,308 Cr.
- Current Price ₹ 170
- High / Low ₹ 194 / 63.5
- Stock P/E 50.6
- Book Value ₹ 31.3
- Dividend Yield 0.26 %
- ROCE 11.4 %
- ROE 10.1 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 5.43 times its book value
- The company has delivered a poor sales growth of 7.28% over past five years.
- Company has a low return on equity of 7.48% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
189 | 217 | 261 | 368 | 402 | 459 | 503 | 547 | 563 | 402 | 545 | 714 | 815 | |
166 | 194 | 234 | 325 | 359 | 406 | 442 | 480 | 501 | 367 | 477 | 620 | 699 | |
Operating Profit | 23 | 23 | 27 | 43 | 43 | 53 | 60 | 66 | 62 | 35 | 68 | 94 | 117 |
OPM % | 12% | 10% | 11% | 12% | 11% | 11% | 12% | 12% | 11% | 9% | 12% | 13% | 14% |
2 | 2 | 1 | 3 | 5 | 4 | 3 | 2 | 4 | 7 | 3 | 7 | 8 | |
Interest | 16 | 15 | 13 | 12 | 9 | 9 | 9 | 11 | 13 | 12 | 11 | 19 | 26 |
Depreciation | 9 | 9 | 9 | 12 | 12 | 15 | 18 | 20 | 22 | 21 | 21 | 29 | 36 |
Profit before tax | 0 | 0 | 7 | 21 | 27 | 32 | 35 | 37 | 32 | 9 | 39 | 53 | 62 |
Tax % | 17% | 0% | 0% | 12% | 21% | 16% | 24% | 44% | 36% | 20% | 16% | 25% | |
0 | 0 | 7 | 19 | 22 | 27 | 27 | 21 | 20 | 7 | 33 | 40 | 46 | |
EPS in Rs | 0.01 | 0.02 | 0.32 | 0.88 | 1.03 | 1.29 | 1.27 | 0.98 | 1.54 | 0.54 | 2.46 | 2.96 | 3.37 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 7% |
3 Years: | 8% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | 59% |
5 Years: | 7% |
3 Years: | 24% |
TTM: | 7% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 97% |
1 Year: | 162% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 7% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 0 | 13 | 13 | 13 | 13 | 14 |
Reserves | 109 | 109 | 116 | 135 | 163 | 183 | 210 | 280 | 301 | 308 | 348 | 393 | 411 |
121 | 118 | 110 | 85 | 68 | 94 | 91 | 114 | 108 | 137 | 190 | 268 | 306 | |
33 | 39 | 66 | 90 | 93 | 124 | 130 | 160 | 159 | 130 | 145 | 207 | 205 | |
Total Liabilities | 284 | 287 | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 937 |
239 | 237 | 236 | 239 | 249 | 283 | 309 | 381 | 387 | 372 | 476 | 584 | 659 | |
CWIP | 0 | 0 | 0 | 0 | 1 | 27 | 43 | 49 | 56 | 81 | 64 | 95 | 54 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 6 | 12 | 15 |
45 | 50 | 77 | 91 | 94 | 112 | 100 | 124 | 137 | 132 | 152 | 192 | 208 | |
Total Assets | 284 | 287 | 313 | 331 | 345 | 422 | 452 | 555 | 581 | 589 | 697 | 882 | 937 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 22 | 45 | 53 | 20 | 58 | 72 | 41 | 56 | 27 | 61 | 129 | |
4 | -5 | -12 | -10 | -14 | -74 | -67 | -50 | -22 | -34 | -106 | -153 | |
-13 | -18 | -21 | -35 | -24 | 19 | -10 | 14 | -33 | 13 | 44 | 30 | |
Net Cash Flow | -3 | -1 | 11 | 7 | -18 | 3 | -4 | 5 | 2 | 6 | -2 | 7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45 | 40 | 41 | 39 | 49 | 48 | 40 | 52 | 50 | 48 | 47 | 43 |
Inventory Days | 32 | 26 | 26 | 26 | 21 | 19 | ||||||
Days Payable | 99 | 144 | 237 | 195 | 189 | 187 | ||||||
Cash Conversion Cycle | -22 | -78 | -171 | -129 | -120 | -120 | 40 | 52 | 50 | 48 | 47 | 43 |
Working Capital Days | 2 | -9 | -70 | -59 | -31 | -44 | -53 | -26 | -28 | -15 | -10 | -29 |
ROCE % | 6% | 6% | 8% | 14% | 15% | 16% | 15% | 14% | 11% | 4% | 10% | 11% |
Documents
Announcements
- Closure of Trading Window 2d
- Disclosure Under The Regulation 30 Of SEBI (LODR) Regulations, 2015 21 Mar
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 19 Mar
- Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 15 Mar
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Feb - Proposed schedule of Investors/ Analysts Meeting with the Company on February 28, 2024.
Specialization-wise revenue break-up:
The revenue stream of AMSL remained well diversified in FY22.
1) Orthopaedics & Joint Replacement contributing (13%)
2) Oncology contributing (18%)
3) Cardiovascular contributing (10%)
4) Neuorologyeurosciences & some others together contributing( 17%)
5) Others incl. Medicine,Gynae,Nephrology etc (42%) [1]